Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Dermatology and Therapy
|
November 4, 2022
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
Benjamin Lockshin, Ryan W Harrison, Robert R McLean, et al.
Paediatric Drugs
|
December 18, 2022
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
Amy S Paller, Elaine C Siegfried, Michael J Cork, et al.
Dermatology and Therapy
|
October 2, 2024
A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis
Andrew F Alexis, Melinda Gooderham, Shawn G Kwatra, et al.
Dermatologic Therapy
|
January 25, 2021
Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry
Benjamin Lockshin, Angel Cronin, Ryan W Harrison, et al.
JAMA Dermatology
|
February 1, 2023
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials
Amy S Paller, Jonathan I Silverberg, Michael J Cork, et al.
Journal of Drugs in Dermatology : JDD
|
August 20, 2019
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials
Andrew F. Alexis, Marta Rendon, Jonathan I. Silverberg, et al.
Cardiovascular Research
|
February 6, 2019
Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study
Youssef A Elnabawi, Amit K Dey, Aditya Goyal, et al.
JAMA Dermatology
|
May 7, 2025
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial
Melinda J Gooderham, Javier Alonso-Llamazares, Jerry Bagel, et al.
JAMA Cardiology
|
August 1, 2019
Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index
Youssef A Elnabawi, Evangelos K Oikonomou, Amit K Dey, et al.
JAMA Dermatology
|
November 7, 2019
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial
Eric L Simpson, Amy S Paller, Elaine C Siegfried, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Dermatology and Therapy
|
November 4, 2022
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
Benjamin Lockshin, Ryan W Harrison, Robert R McLean, et al.
Paediatric Drugs
|
December 18, 2022
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
Amy S Paller, Elaine C Siegfried, Michael J Cork, et al.
Dermatology and Therapy
|
October 2, 2024
A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis
Andrew F Alexis, Melinda Gooderham, Shawn G Kwatra, et al.
Dermatologic Therapy
|
January 25, 2021
Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry
Benjamin Lockshin, Angel Cronin, Ryan W Harrison, et al.
JAMA Dermatology
|
February 1, 2023
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials
Amy S Paller, Jonathan I Silverberg, Michael J Cork, et al.
Journal of Drugs in Dermatology : JDD
|
August 20, 2019
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials
Andrew F. Alexis, Marta Rendon, Jonathan I. Silverberg, et al.
Cardiovascular Research
|
February 6, 2019
Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study
Youssef A Elnabawi, Amit K Dey, Aditya Goyal, et al.
JAMA Dermatology
|
May 7, 2025
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial
Melinda J Gooderham, Javier Alonso-Llamazares, Jerry Bagel, et al.
JAMA Cardiology
|
August 1, 2019
Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index
Youssef A Elnabawi, Evangelos K Oikonomou, Amit K Dey, et al.
JAMA Dermatology
|
November 7, 2019
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial
Eric L Simpson, Amy S Paller, Elaine C Siegfried, et al.
Page
of 3